Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Weldon Takes Compensation Hit Due To OTC Recalls, But J&J Touts His Steering

This article was originally published in The Tan Sheet

Executive Summary

Johnson & Johnson's manufacturing woes nicked CEO William Weldon’s 2010 compensation, but so far the firm's board of directors continues to stand behind him.

You may also be interested in...



McNeil OTC Recalls Slice $900M From J&J's 2010 Sales

Recalled OTC drugs took a $900 million bite out of Johnson & Johnson's fiscal 2010 sales, including $300 million in the fourth quarter, contributing to what the company and analysts labeled disappointing earnings.

J&J/McNeil Done With Post-Recall Personnel Changes - CEO Weldon

Johnson & Johnson has finished culling its ranks of employees responsible for quality control lapses that led to extensive OTC recalls, according to CEO William Weldon.

Along With All NDAs Submitted To US FDA In FY2023, Costs For OTC Switch Proposals Increase

Agency publishes Prescription Drug User Fee Act rates for FY2023, the first of five covered in reauthorization of program Congress approved on 30 September as legislation added to a continuing resolution to fund federal agencies through 16 December.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS104942

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel